Initiation of semaglutide and other GLP-1 therapies
You may have seen a recent email on 19/11/26 from SBUHB regarding the Interim position on initiation of semaglutide and other GLP-1 therapies (below). Specific guidance for when these medications can be prescribed can be found on our FAQ page and there are also Practice information leaflets and Patient information leaflets you can use. Please do reach out if you have any queries.
"Dear Service Group Medical Directors,
I am writing to clarify the Health Board’s current position regarding initiation of semaglutide, and other GLP-1 receptor agonist therapies, where newly recommended indications require an ongoing prescribing pathway that is not yet in place.
Although national guidance supports semaglutide for some additional indications, Swansea Bay is currently unable to implement all of these recommendations. In particular, for semaglutide in patients with established cardiovascular disease, there is presently no agreed mechanism to support long-term prescribing and clinical follow-up after initiation. This remains under discussion nationally, including the respective roles of primary and secondary care.
Pending resolution of these arrangements, clinicians should not initiate semaglutide, or another GLP-1 therapy for an equivalent newly recommended indication, unless there is an established and funded pathway that provides for ongoing prescribing and monitoring. This is intended to avoid patients being started on treatment without a sustainable mechanism for continuation.
This does not affect established GLP-1 prescribing pathways for indications where appropriate commissioning and ongoing prescribing arrangements are already in place.
Please could you cascade this position to relevant clinical teams within your Service Group. We will provide a further update when a sustainable prescribing pathway has been agreed.
Many thanks,
Dr Mark Ramsey
Interim Deputy Executive Medical Director"

